Cargando…

Trends in industrialization and commercialization of IgY technology

IgY technology refers to the strategic production process involved in generating avian immunoglobulin (IgY) against target antigens in a much more cost-effective manner with broad applications in the fields of diagnostics, prophylaxis, and therapeutics for both human and veterinary medicine. Over th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yakhkeshi, Saeed, Wu, Rao, Chelliappan, Brindha, Zhang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630564/
https://www.ncbi.nlm.nih.gov/pubmed/36341353
http://dx.doi.org/10.3389/fimmu.2022.991931
_version_ 1784823629890977792
author Yakhkeshi, Saeed
Wu, Rao
Chelliappan, Brindha
Zhang, Xiaoying
author_facet Yakhkeshi, Saeed
Wu, Rao
Chelliappan, Brindha
Zhang, Xiaoying
author_sort Yakhkeshi, Saeed
collection PubMed
description IgY technology refers to the strategic production process involved in generating avian immunoglobulin (IgY) against target antigens in a much more cost-effective manner with broad applications in the fields of diagnostics, prophylaxis, and therapeutics for both human and veterinary medicine. Over the past decade, promising progress in this research area has been evident from the steep increase in the number of registered manufacturing companies involved in the production of IgY products, the number of patents, and the notable number of clinical trials underway. Hence, it is crucial to conduct a prospective analysis of the commercialization and marketing potential of IgY-based commercial products for large-scale applications. This review revealed that the number of IgY patent applications increased steeply after 2010, with the highest of 77 patents filed in 2021. In addition, 73 industries are reportedly involved in marketing IgY products, out of which 27 were promoting biotherapeutics for human and veterinary medicine and 46 were in the diagnostic field. IgY antibodies are being used as primary and secondary antibodies, with approximately 3729 and 846 products, respectively. Biotherapeutic product consumption has notably increased as a food supplement and as a topical application in human and veterinary medicine, which are under different clinical phases of development to reach the market with around 80 and 56 products, respectively. In contrast, the number of IgY products as parenteral administrations and licensed drugs is not well developed given the lack of technical standards established for IgY registration and industrialization, as well as the restriction of the nature of polyclonal antibodies. However, recent ongoing research on functional IgY fragments indicates a promising area for IgY applications in the near future. Therefore, retrospective analysis with speculations is mandatory for IgY technology maturation toward industrialization and commercialization.
format Online
Article
Text
id pubmed-9630564
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96305642022-11-04 Trends in industrialization and commercialization of IgY technology Yakhkeshi, Saeed Wu, Rao Chelliappan, Brindha Zhang, Xiaoying Front Immunol Immunology IgY technology refers to the strategic production process involved in generating avian immunoglobulin (IgY) against target antigens in a much more cost-effective manner with broad applications in the fields of diagnostics, prophylaxis, and therapeutics for both human and veterinary medicine. Over the past decade, promising progress in this research area has been evident from the steep increase in the number of registered manufacturing companies involved in the production of IgY products, the number of patents, and the notable number of clinical trials underway. Hence, it is crucial to conduct a prospective analysis of the commercialization and marketing potential of IgY-based commercial products for large-scale applications. This review revealed that the number of IgY patent applications increased steeply after 2010, with the highest of 77 patents filed in 2021. In addition, 73 industries are reportedly involved in marketing IgY products, out of which 27 were promoting biotherapeutics for human and veterinary medicine and 46 were in the diagnostic field. IgY antibodies are being used as primary and secondary antibodies, with approximately 3729 and 846 products, respectively. Biotherapeutic product consumption has notably increased as a food supplement and as a topical application in human and veterinary medicine, which are under different clinical phases of development to reach the market with around 80 and 56 products, respectively. In contrast, the number of IgY products as parenteral administrations and licensed drugs is not well developed given the lack of technical standards established for IgY registration and industrialization, as well as the restriction of the nature of polyclonal antibodies. However, recent ongoing research on functional IgY fragments indicates a promising area for IgY applications in the near future. Therefore, retrospective analysis with speculations is mandatory for IgY technology maturation toward industrialization and commercialization. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9630564/ /pubmed/36341353 http://dx.doi.org/10.3389/fimmu.2022.991931 Text en Copyright © 2022 Yakhkeshi, Wu, Chelliappan and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Yakhkeshi, Saeed
Wu, Rao
Chelliappan, Brindha
Zhang, Xiaoying
Trends in industrialization and commercialization of IgY technology
title Trends in industrialization and commercialization of IgY technology
title_full Trends in industrialization and commercialization of IgY technology
title_fullStr Trends in industrialization and commercialization of IgY technology
title_full_unstemmed Trends in industrialization and commercialization of IgY technology
title_short Trends in industrialization and commercialization of IgY technology
title_sort trends in industrialization and commercialization of igy technology
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630564/
https://www.ncbi.nlm.nih.gov/pubmed/36341353
http://dx.doi.org/10.3389/fimmu.2022.991931
work_keys_str_mv AT yakhkeshisaeed trendsinindustrializationandcommercializationofigytechnology
AT wurao trendsinindustrializationandcommercializationofigytechnology
AT chelliappanbrindha trendsinindustrializationandcommercializationofigytechnology
AT zhangxiaoying trendsinindustrializationandcommercializationofigytechnology